Impact Biomedical IBO
NYSE IBO
$5.32 -0.14 (-2.56%)
At close: Oct 2, 2026 · 4:00 PM EDT

Impact Biomedical (IBO) Price to Sales (2025 - 2026)

Updated

Impact Biomedical's (IBO) Price to Sales stood at 1417.08 in Q2 2026, up 919.8% from 138.96 a year earlier but down 29.9% from the prior quarter.

Analysis

Impact Biomedical (IBO) Price to Sales (2025 - 2026) Analysis & Trends

Starting with Q2 2025, Impact Biomedical's Price to Sales history includes 4 quarters.

  • Quarterly Price to Sales has ranged from 138.96 in Q2 2025 to 2021.65 in Q1 2026 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Impact Biomedical 573.61 Mn 576.81 Mn 2,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1,417.08
Mar 31, 2026 2,021.65
Sep 30, 2025 326.57
Jun 30, 2025 138.96
API Access

Impact Biomedical Price to Sales API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-sales&ticker=IBO&period=max&api_key=YOUR_API_KEY